Pulmonary Embolism Clinical Trial
Official title:
Right Ventricular Dysfunction in Acute Pulmonary Embolism as Assessed by Spiral CT Scan: Comparison With Transthoracic Echocardiography and Evaluation of Prognostic Value
This is a prospective, observational, multicenter study. The primary aim of the study is to
assess the accuracy of spiral CT scan to detect right ventricular dysfunction as compared to
current 'gold standard'in patients with pulmonary embolism. At the purpose of this study
right ventricular dysfunction as assessed by transthoracic echocardiography and serum levels
of troponin are considered as gold standard.
The secondary aim of the study is to assess the prognostic value of right ventricular
dysfunction as assessed by spiral CT scan.
Pulmonary embolism (PE) is a common and life-threatening disease. The incidence of a first
episode of PE in acute care hospitals in the United States has been found to be 0.23 per
1000 with in-hospital mortality ranging from 30%, in case of cardiogenic shock, to about 0%
in absence of right ventricular overload or hemodinamic impairment (1). In the intermediate
group of patients with right ventricular overload but no hemodinamic impairment, in hospital
mortality has been assessed to be about 5%. Right ventricular dysfunction as assessed at
echocardiography and serum levels of Troponin I and T have been proposed as qualifying
criteria for the identification of a subgroup of patients with pulmonary embolism and no
hemodinamic impairment at high risk for in-hospital death. These patients could potentially
benefit from more aggressive treatment.
A number of studies reported in favor of the association between echocardiographic RVD and
early adverse outcome (PE recurrence and mortality) in patients with acute PE (3-6).
In-hospital mortality in PE patients with and without echocardiographic RVD has been found
to be 18.4% and 5.7%, respectively, regardless of the hemodinamic status (3). In 126
patients with acute pulmonary embolism, Ribeiro et al. reported a 7.9% overall in-hospital
mortality (7). Mortality was 14.3% in patients with severe RVD. In a cohort of 2454
unselected patients with acute pulmonary embolism included in the ICOPER registry, 2-week
mortality was 15.9% in patients presenting with RVD in comparison to 8% in patients without
RVD (8). In the MAPPET 10% of patients with RVD died within 30 days as compared to 4.1% of
patients without (9). Recent data confirmed that patients with objectively confirmed PE,
normal BP and echocardiographic evidence of RVD have a high incidence of adverse outcome and
may potentially benefit from more aggressive treatment (10).
Troponin I and T levels have also been described to be associated with in-hospital mortality
and adverse in-hospital outcome in patients with acute pulmonary embolism (13-15).
In small studies with helical CT, the ratio of the right ventricle to left ventricle short
axis diameters (RV/LV) has been proposed as an accurate sign for the presence of RVD
(16-19). In addition, other criteria have been proposed, including deviation of the
interventricular septum and the ratio of the pulmonary artery to ascending aorta diameters.
Also, the extent of PE (ie, thrombus burden in the pulmonary arteries) has been proposed as
an important parameter for predicting RVD (20-21). In a recent retrospective study in 120
patients with pulmonary embolism, seven patients died of PE. Both the RV/LV ratio and the
obstruction index were shown to be significant risk factors for 3-month mortality (p = 0.04
and 0.01, respectively). No such relationship was found for the ratio of the pulmonary
artery to ascending aorta diameters (p= 0.66) or for the shape of the interventricular
septum (p = 0.20). The positive predictive value for PE-related mortality with an RV/LV
ratio greater than 1.0 was 10.1% (95% confidence interval [CI]: 2.9%, 17.4%). The negative
predictive value for an uneventful outcome with an RV/LV ratio of 1.0 or less was 100% (95%
CI: 94.3%, 100%). There was a 11.2-fold increased risk of dying of PE for patients with an
obstruction index of 40% or higher (95% CI: 1.3, 93.6). The CT obstruction index (29% ± 17%)
and the Miller index (43% ± 25%) were well correlated (r = 0.867, p < 0.0001) with an
excellent concordance between investigators for both the CT index (r = 0.944, p < 0.0001)
and the Miller index (r = 0.904, p < 0.0001). A CT obstruction index greater than 40%
identified more than 90% of patients with right ventricular dilatation.
Aim of the study The primary aim of the study is to assess the accuracy of spiral CT scan to
detect right ventricular dysfunction as compared to current 'gold standard'. At the purpose
of this study right ventricular dysfunction as assessed by transthoracic echocardiography
and serum levels of troponin are considered as gold standard.
The secondary aim of the study is to assess the prognostic value of right ventricular
dysfunction as assessed by spiral CT scan.
Feasibility In order to reach 200 evaluable patients, the Radiology Units of the
participating centers will be asked to alert local investigators regarding all the patients
with CT scan positive for acute pulmonary embolism. Local investigators should take care of
organizing transthoracic echocardiography and troponin levels.
Four centers are required in order to complete the study in one year.
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05050617 -
Point-of-Care Ultrasound in Predicting Adverse Outcomes in Emergency Department Patients With Acute Pulmonary Embolism
|
||
| Terminated |
NCT04558125 -
Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism
|
Phase 4 | |
| Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
| Completed |
NCT03915925 -
Short-term Clinical Deterioration After Acute Pulmonary Embolism
|
||
| Completed |
NCT02502396 -
Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center
|
||
| Recruiting |
NCT05171075 -
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
|
Phase 3 | |
| Completed |
NCT04454554 -
Prevalence of Pulmonary Embolism in Patients With Dyspnea on Exertion (PEDIS)
|
||
| Completed |
NCT03173066 -
Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography
|
Phase 1 | |
| Terminated |
NCT03002467 -
Impact Analysis of Prognostic Stratification for Pulmonary Embolism
|
N/A | |
| Completed |
NCT02611115 -
Optimizing Protocols for the Individual Patient in CT Pulmonary Angiography.
|
N/A | |
| Completed |
NCT02334007 -
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
|
Phase 1/Phase 2 | |
| Completed |
NCT01975090 -
The SENTRY Clinical Study
|
N/A | |
| Not yet recruiting |
NCT01357941 -
Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE)
|
N/A | |
| Completed |
NCT01326507 -
Prognostic Value of Heart-type Fatty Acid-Binding Protein (h-FABP) in Acute Pulmonary Embolism
|
N/A | |
| Completed |
NCT00773448 -
Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism
|
N/A | |
| Completed |
NCT02476526 -
Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease
|
Phase 4 | |
| Completed |
NCT00771303 -
Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study
|
||
| Completed |
NCT00720915 -
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
|
N/A | |
| Completed |
NCT00780767 -
Angiojet Rheolytic Thrombectomy in Case of Massive Pulmonary Embolism
|
Phase 2 | |
| Completed |
NCT00244725 -
Odiparcil For The Prevention Of Venous Thromboembolism
|
Phase 2 |